AMPX Q2 Results Confirm Guidance Raise on Drone Strength, But Manufacturing Execution Still Key

What happened

Amprius Technologies reported Q2 2026 revenue of $34.0 million, more than doubling year-over-year, and raised full-year guidance to at least $140.0 million in revenue and at least 28% gross margin, citing accelerating drone demand and a large European order. The quarter demonstrated strong commercial traction, with gross margin improving to 27% from 11% in FY2025, though adjusted EBITDA remained slightly negative at -$1.0 million. Management attributed the improved outlook to SiCore product mix, repeat UAS orders, and better manufacturing economics under its capital-light, partner-dependent model. However, working capital pressure mounted as accounts receivable swelled to $40.7 million from $23.7 million, and operating cash burn widened, underscoring that order-to-cash conversion is still unproven. The news reinforces the demand thesis but leaves unanswered whether outsourced partners can deliver the required quality and yield to sustain margins and reach self-funded scale.

Implication

The raised outlook validates that Amprius’s premium silicon-anode cells are gaining commercial adoption in defense and drone end-markets, aligning with our base case. Near-term, the stock’s reaction will hinge on whether H2 revenue pacing toward the $140 million target holds when Q3 results are reported, especially given the heavy reliance on a few large customers. Gross margin durability above 28% is critical; any slip would signal that mix benefits are not yet structural. The capital-light model keeps capex low but elevates execution risk with contract manufacturers, making NDAA compliance and partner throughput the next major checkpoints. Until the company demonstrates it can convert bookings into cash without further working-capital strain, the risk-reward remains unattractive above our attractive entry level.

Thesis delta

The Q2 results and guidance raise strengthen the demand side of the thesis but do not resolve the key risk around outsourced manufacturing execution. Our WAIT rating is maintained because the company still must prove it can convert strong drone orders into profitable, cash-generating scale without partner bottlenecks or dilution. No change to conviction or valuation scenarios is warranted until Q3 confirms revenue pacing and margin durability.